Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training

[1]  I. Bautmans,et al.  Six weeks of strength endurance training decreases circulating senescence-prone T-lymphocytes in cytomegalovirus seropositive but not seronegative older women , 2019, Immunity & Ageing.

[2]  I. Bautmans,et al.  Impact of drugs with anti-inflammatory effects on skeletal muscle and inflammation: A systematic literature review , 2018, Experimental Gerontology.

[3]  L. Ferrucci,et al.  International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management , 2018, The journal of nutrition, health & aging.

[4]  I. Bautmans,et al.  Strength endurance training but not intensive strength training reduces senescence-prone T-cells in peripheral blood in community-dwelling elderly women. , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

[5]  René Rizzoli,et al.  Sarcopenia: revised European consensus on definition and diagnosis , 2018, Age and ageing.

[6]  S. Vermeiren,et al.  Association Between Immunosenescence Phenotypes and Pre-frailty in Older Subjects: Does Cytomegalovirus Play a Role? , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

[7]  Y. Fujiwara,et al.  Association between statin use and physical function among community‐dwelling older Japanese adults , 2018, Geriatrics & gerontology international.

[8]  M. Tinetti,et al.  Guideline‐Recommended Medications and Physical Function in Older Adults with Multiple Chronic Conditions , 2017, Journal of the American Geriatrics Society.

[9]  P. Thompson,et al.  The effects of statins on exercise and physical activity. , 2017, Journal of clinical lipidology.

[10]  M. Veríssimo,et al.  Exercise training improves functional status in hypertensive older adults under angiotensin converting enzymes inhibitors medication , 2017, Experimental Gerontology.

[11]  H. Völzke,et al.  Statins are related to impaired exercise capacity in males but not females , 2017, PloS one.

[12]  E. Steinhagen-Thiessen,et al.  Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II) , 2016, Drugs & Aging.

[13]  M. Serra-Prat,et al.  Oral Drugs Related with Muscle Wasting and Sarcopenia. A Review , 2016, Pharmacology.

[14]  J. Verghese,et al.  Gait Performance in Hypertensive Patients on Angiotensin-Converting Enzyme Inhibitors. , 2016, Journal of the American Medical Directors Association.

[15]  R. Halfens,et al.  Burden-of-illness of Dutch community-dwelling older adults with sarcopenia: health related outcomes and costs , 2016 .

[16]  G. Peeters,et al.  Associations Between Statin Use and Physical Function in Older Adults from The Netherlands and Australia: Longitudinal Aging Study Amsterdam and Australian Longitudinal Study on Women’s Health , 2016, Drugs & Aging.

[17]  V. Probst,et al.  Angiotensin-II blockage, muscle strength, and exercise capacity in physically independent older adults , 2016, Journal of physical therapy science.

[18]  B. Tomlinson,et al.  Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia , 2015, Lipids in Health and Disease.

[19]  Y. Chang,et al.  Angiotensin II in inflammation, immunity and rheumatoid arthritis , 2015, Clinical and experimental immunology.

[20]  Jeffrey R Stout,et al.  Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS) , 2014, Age and ageing.

[21]  P. Cawthon,et al.  Statins and physical activity in older men: the osteoporotic fractures in men study. , 2014, JAMA internal medicine.

[22]  L. Vilá,et al.  Association of the use of statins with disease activity and functional status in Puerto Ricans with rheumatoid arthritis. , 2014, Puerto Rico health sciences journal.

[23]  C. Tzourio,et al.  Lipid-lowering drugs associated with slower motor decline in the elderly adults. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[24]  M. Mcmurdo,et al.  Do ACE Inhibitors Improve the Response to Exercise Training in Functionally Impaired Older Adults? A Randomized Controlled Trial , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[25]  M. Levy,et al.  Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial. Journal of the American Medical Association 2013; 309: 453–460 , 2013, Vascular medicine.

[26]  Rose Anne Kenny,et al.  Using timed up-and-go to identify frail members of the older population. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[27]  C. Reid,et al.  Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. , 2013, JAMA.

[28]  M. Brotto,et al.  Sarcopenia: Pharmacology of Today and Tomorrow , 2012, Journal of Pharmacology and Experimental Therapeutics.

[29]  Jennifer G. Robinson,et al.  Statins, Angiotensin‐Converting Enzyme Inhibitors, and Physical Performance in Older Women , 2012, Journal of the American Geriatrics Society.

[30]  P. Thompson,et al.  Effect of Statins on Skeletal Muscle Function , 2012, Circulation.

[31]  S. Anton,et al.  Angiotensin‐Converting Enzyme Inhibitor Use by Older Adults Is Associated with Greater Functional Responses to Exercise , 2012, Journal of the American Geriatrics Society.

[32]  K. Channon,et al.  Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials , 2012, Current pharmaceutical design.

[33]  M. Bernabeu-Wittel,et al.  Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients. , 2012, European journal of internal medicine.

[34]  Martin R. Lindley,et al.  The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease , 2011, Nature Reviews Immunology.

[35]  G. Onder,et al.  Current and future pharmacologic treatment of sarcopenia. , 2011, Clinics in geriatric medicine.

[36]  F. Lattanzio,et al.  Targeting inflammation to slow or delay functional decline: where are we? , 2010, Biogerontology.

[37]  P. Joshi,et al.  Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment , 2010, Current atherosclerosis reports.

[38]  J. Woo,et al.  Defining Sarcopenia in Terms of Risk of Physical Limitations: A 5‐Year Follow‐Up Study of 3,153 Chinese Men and Women , 2009, Journal of the American Geriatrics Society.

[39]  G. Onder,et al.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia , 2009, The journal of nutrition, health & aging.

[40]  L. Blizzard,et al.  Statin therapy, muscle function and falls risk in community-dwelling older adults. , 2009, QJM : monthly journal of the Association of Physicians.

[41]  B. Miller,et al.  The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. , 2009, Journal of applied physiology.

[42]  S. Kritchevsky,et al.  Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. , 2009, American heart journal.

[43]  M. Mcmurdo,et al.  ACE inhibitors as a therapy for sarcopenia — Evidence and possible mechanisms , 2008, The journal of nutrition, health & aging.

[44]  M. Mcmurdo,et al.  ACE inhibitors for sarcopenia--as good as exercise training? , 2008, Age and ageing.

[45]  B. Horne,et al.  Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing. , 2007, The American journal of cardiology.

[46]  M. Mcmurdo,et al.  Sarcopenia – A Potential Target for Angiotensin-Converting Enzyme Inhibition? , 2006, Gerontology.

[47]  M. Pahor,et al.  Effects of ACE inhibitors on skeletal muscle. , 2006, Current pharmaceutical design.

[48]  R. Devereux,et al.  Exercise performance during losartan‐ or atenolol‐based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy) , 2006, Blood pressure.

[49]  A. Ducharme,et al.  Angiotensin Receptor Blockade and Exercise Capacity in Adults With Systemic Right Ventricles: A Multicenter, Randomized, Placebo-Controlled Clinical Trial , 2005, Circulation.

[50]  Tony Mets,et al.  A fatigue resistance test for elderly persons based on grip strength: reliability and comparison with healthy young subjects , 2005, Aging clinical and experimental research.

[51]  Tony Mets,et al.  The six-minute walk test in community dwelling elderly: influence of health status. , 2004, BMC geriatrics.

[52]  M. Lye,et al.  The Effect of Quinapril on Functional Status of Elderly Patients with Diastolic Heart Failure , 2003, Cardiovascular Drugs and Therapy.

[53]  T. Mets,et al.  The 6-minute walk as an appropriate exercise test in elderly patients with chronic heart failure. , 1996, The journals of gerontology. Series A, Biological sciences and medical sciences.

[54]  H. Müller-Hermelink,et al.  Admission criteria for immunogerontological studies in man: The senieur protocol , 1984, Mechanisms of Ageing and Development.

[55]  J. Reid,et al.  Lecture Notes on Clinical Pharmacology , 1982 .

[56]  M. Cesari,et al.  ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. , 2010, Journal of the American Medical Directors Association.